Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial

Incorporating LiverMultiScan into the MASLD diagnostic pathway is cost-effective, significantly reduces the number of specialist appointments, patient assessments, and rate of diagnosis without increasing other liver-related health care resource use. cT1 also correctly classified 50% of patients without MASH with fibrosis who could avoid biopsy. Standardized adoption of LiverMultiScan can streamline clinical pathways, lower costs, and improve long-term management.